The U.S. Food and Drug Administration (FDA) has added BPC-157-related substances to the agenda of the Pharmacy Compounding Advisory Committee (PCAC) scheduled for July 23, 2026. The meeting is part of the FDA's long-running evaluation of bulk drug substances nominated for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
What the PCAC does
The PCAC advises the FDA on whether specific bulk drug substances should be placed on the 503A bulks list — the list of ingredients licensed compounders may legally use when preparing patient-specific compounded medications. A PCAC discussion does not by itself approve or prohibit a substance; it produces a recommendation that the FDA ultimately considers in a formal rulemaking process.
Advisory committee meetings are public events. The FDA typically publishes briefing documents — often dense technical files — in advance of the meeting. These documents summarize available evidence on a substance's chemistry, safety, and effectiveness. Our job is to translate those materials into plain language as soon as they become available.
Why BPC-157 is on the agenda
BPC-157 is a synthetic peptide that has attracted growing consumer interest, but the FDA has previously raised safety signals around certain compounded peptide products and flagged gaps in human clinical data. Re-examining BPC-157 in a formal PCAC meeting creates a structured, public forum to review the available evidence.
The formal nomination process for the 503A bulks list requires a petitioner to submit supporting data. BPC-157-related substances advanced through this process in 2025, triggering the scheduled July 2026 hearing. The scheduling itself is neutral — it reflects the process working, not a pre-judgment about outcome.
What this is not
- This is not an FDA approval of BPC-157.
- This is not a guarantee that BPC-157 will be added to — or removed from — the 503A bulks list.
- This does not change the current U.S. status of BPC-157.
- This is not a signal that BPC-157 will become available for purchase or prescription after the meeting.
What happens at the PCAC meeting
PCAC meetings typically follow a structured agenda. For each substance under discussion, the committee hears from FDA staff presenting their evidence review, may hear from the nominator or public commenters, and then deliberates before voting on a recommendation. The recommendation categories include: favorable for inclusion, not favorable for inclusion, or deferred pending additional data.
The FDA is not bound by the committee's recommendation but historically follows it in most cases. Following a recommendation, any actual change to the 503A bulks list requires formal rulemaking — a notice of proposed rulemaking, public comment period, and final rule.
What to watch
Briefing documents typically become publicly available in the weeks leading up to a PCAC meeting. Those documents usually contain the FDA's own review of physicochemical characterization, safety data, effectiveness evidence, and historical use. We will summarize those materials as they become available — within 24 hours of release, with plain-language context.
Subscribers to BPC157.now will receive an email notification when we publish briefing summaries. The materials will also appear on our news page and regulatory tracker.
